Brooke J Arterberry1, Hayley Treloar Padovano2, Katherine T Foster3, Robert A Zucker4, Brian M Hicks5. 1. Department of Psychology, Iowa State University, 901 Stange Road, Ames, IA 50011-1041, USA. Electronic address: barterb@iastate.edu. 2. Department of Psychiatry and Human Behavior, Center for Alcohol and Addiction Studies, Brown University, 121 South Main Street, Providence, RI 02903 USA. Electronic address: hayley_treloar@brown.edu. 3. Department of Psychology, University of Michigan, 530 Church St., Ann Arbor, MI 48105 USA. Electronic address: ktfoster@umich.edu. 4. Department of Psychiatry, University of Michigan Addiction Center, 4250 Plymouth Road, Ann Arbor, MI 48109 USA. Electronic address: zuckerra@med.umich.edu. 5. Department of Psychiatry, University of Michigan Addiction Center, 4250 Plymouth Road, Ann Arbor, MI 48109 USA. Electronic address: brianhic@med.umich.edu.
Abstract
OBJECTIVE: To determine if higher potency cannabis is associated with earlier progression to regular cannabis use, daily cannabis use, and cannabis use disorder symptom onset. METHODS: Data sources were the Michigan Longitudinal Study, an ongoing prospective, high-risk family study investigating the course and predictors for substance use disorders among youth beginning prior to school entry and time-parallel national average trends in delta-9-tetrahydrocannabinol (i.e., psychoactive compound in cannabis). The national average trends in delta-9-tetrahydrocannabinol were used to estimate potency level for the individual. Only cannabis users were included in analyses (n = 527). RESULTS: Cox regression showed an increased risk of progression from cannabis initiation to cannabis use disorder symptom onset by 1.41 times (p < .001) for each unit increase in national average delta-9-tetrahydrocannabinol as compared to those not endorsing CUD symptom onset, adjusting for sex, regular use, and cohort effects. Accounting for regular use, individuals initiating cannabis at national average 4.9% delta-9-tetrahydrocannabinol were at 1.88 times (p = .012) higher risk for cannabis use disorder symptom onset within one year compared to those who did not endorse CUD symptom onset, while those initiating cannabis at national average 12.3% delta-9-tetrahydrocannabinol were at 4.85 times (p = .012) higher risk within one year. CONCLUSIONS: This study provides prospective evidence suggesting higher potency cannabis, on average in the U.S., increases risk for onset of first cannabis use disorder symptom. Development of guidelines regarding cannabis potency is critical for reducing the costs associated with negative health outcomes.
OBJECTIVE: To determine if higher potency cannabis is associated with earlier progression to regular cannabis use, daily cannabis use, and cannabis use disorder symptom onset. METHODS: Data sources were the Michigan Longitudinal Study, an ongoing prospective, high-risk family study investigating the course and predictors for substance use disorders among youth beginning prior to school entry and time-parallel national average trends in delta-9-tetrahydrocannabinol (i.e., psychoactive compound in cannabis). The national average trends in delta-9-tetrahydrocannabinol were used to estimate potency level for the individual. Only cannabis users were included in analyses (n = 527). RESULTS:Cox regression showed an increased risk of progression from cannabis initiation to cannabis use disorder symptom onset by 1.41 times (p < .001) for each unit increase in national average delta-9-tetrahydrocannabinol as compared to those not endorsing CUD symptom onset, adjusting for sex, regular use, and cohort effects. Accounting for regular use, individuals initiating cannabis at national average 4.9% delta-9-tetrahydrocannabinol were at 1.88 times (p = .012) higher risk for cannabis use disorder symptom onset within one year compared to those who did not endorse CUD symptom onset, while those initiating cannabis at national average 12.3% delta-9-tetrahydrocannabinol were at 4.85 times (p = .012) higher risk within one year. CONCLUSIONS: This study provides prospective evidence suggesting higher potency cannabis, on average in the U.S., increases risk for onset of first cannabis use disorder symptom. Development of guidelines regarding cannabis potency is critical for reducing the costs associated with negative health outcomes.
Authors: Peggy van der Pol; Nienke Liebregts; Ron de Graaf; Dirk J Korf; Wim van den Brink; Margriet van Laar Journal: Drug Alcohol Depend Date: 2013-07-22 Impact factor: 4.492
Authors: Silvia S Martins; Christine M Mauro; Julian Santaella-Tenorio; June H Kim; Magdalena Cerda; Katherine M Keyes; Deborah S Hasin; Sandro Galea; Melanie Wall Journal: Drug Alcohol Depend Date: 2016-10-11 Impact factor: 4.492
Authors: Marta Di Forti; Craig Morgan; Paola Dazzan; Carmine Pariante; Valeria Mondelli; Tiago Reis Marques; Rowena Handley; Sonija Luzi; Manuela Russo; Alessandra Paparelli; Alexander Butt; Simona A Stilo; Ben Wiffen; John Powell; Robin M Murray Journal: Br J Psychiatry Date: 2009-12 Impact factor: 9.319
Authors: Deborah S Hasin; Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Bridget F Grant Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: S Rigucci; T R Marques; M Di Forti; H Taylor; F Dell'Acqua; V Mondelli; S Bonaccorso; A Simmons; A S David; P Girardi; C M Pariante; R M Murray; P Dazzan Journal: Psychol Med Date: 2015-11-27 Impact factor: 10.592
Authors: Deborah S Hasin; Jacob Borodovsky; Dvora Shmulewitz; Claire Walsh; Ofir Livne; Cara A Struble; Efrat Aharonovich; David S Fink; Alan Budney Journal: Drug Alcohol Depend Date: 2021-10-29 Impact factor: 4.492
Authors: Deborah S Hasin; Andrew J Saxon; Carol Malte; Mark Olfson; Katherine M Keyes; Jaimie L Gradus; Magdalena Cerdá; Charles C Maynard; Salomeh Keyhani; Silvia S Martins; David S Fink; Ofir Livne; Zachary Mannes; Melanie M Wall Journal: Am J Psychiatry Date: 2022-07-28 Impact factor: 19.242
Authors: Sean Esteban McCabe; Brooke J Arterberry; Kara Dickinson; Rebecca J Evans-Polce; Jason A Ford; Jennie E Ryan; Ty S Schepis Journal: JAMA Pediatr Date: 2021-01-01 Impact factor: 16.193
Authors: Katherine L McPherson; Dardo G Tomasi; Gene-Jack Wang; Peter Manza; Nora D Volkow Journal: Front Psychiatry Date: 2021-05-13 Impact factor: 4.157
Authors: Christine M Steeger; Leah N Hitchcock; Angela D Bryan; Kent E Hutchison; Karl G Hill; L Cinnamon Bidwell Journal: Int J Drug Policy Date: 2021-05-30